Literature DB >> 1867265

CHARGE association: clinical manifestations and developmental outcome.

A S Harvey1, P M Leaper, A Bankier.   

Abstract

Mental retardation and growth failure are considered integral manifestations in the CHARGE association, reported to be present in as many as 90% of cases. Recent studies have reported a better than expected outcome in some patients; however, the conclusions of these studies have been confounded to some extent by their inclusion criteria. We report follow-up of 17 patients with CHARGE association in whom the diagnosis was based on clinical findings present in early infancy, before developmental patterns were established. Of the 7 survivors, all had motor delay, and 6 had feeding difficulties during infancy. Psychometric assessment at follow-up (age range 2 years, 10 months, to 15 years) showed that 2 were functioning in the normal range, 3 had specific language delay, one had moderate mental retardation, and one had severe mental retardation. Feeding problems persisted in only the 2 youngest patients. After initial failure to thrive, normal height was reached in 4 of 5 children older than age 3 years. The effects of visual and hearing deficits, their management, and the effects of physical illness are discussed with respect to developmental outcome. Our results suggest that some infants with CHARGE association who survive early infancy have a better prognosis for feeding difficulties, growth, and mental development than may be expected from early performance and better than that generally predicted from the current literature. The prompt management of sensory deficits is emphasized.

Entities:  

Mesh:

Year:  1991        PMID: 1867265     DOI: 10.1002/ajmg.1320390112

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  8 in total

1.  A new lethal syndrome of exomphalos, short limbs, and macrogonadism.

Authors:  L Faivre; A L Delezoide; F Narcy; F Razavi; R Bouvier; V Cormier-Daire; M L Briard; S Lyonnet; M Vekemans; A Munnich; M Le Merrer
Journal:  J Med Genet       Date:  1999-02       Impact factor: 6.318

2.  Early oral sensory experiences and feeding development in children with CHARGE syndrome: a report of five cases.

Authors:  Cindy Dobbelsteyn; Darlene M Marche; Kim Blake; Mohsin Rashid
Journal:  Dysphagia       Date:  2005       Impact factor: 3.438

3.  Phenotypic spectrum of CHARGE syndrome in fetuses with CHD7 truncating mutations correlates with expression during human development.

Authors:  D Sanlaville; H C Etchevers; M Gonzales; J Martinovic; M Clément-Ziza; A-L Delezoide; M-C Aubry; A Pelet; S Chemouny; C Cruaud; S Audollent; C Esculpavit; G Goudefroye; C Ozilou; C Fredouille; N Joye; N Morichon-Delvallez; Y Dumez; J Weissenbach; A Munnich; J Amiel; F Encha-Razavi; S Lyonnet; M Vekemans; T Attié-Bitach
Journal:  J Med Genet       Date:  2005-09-16       Impact factor: 6.318

4.  Growth failure and pituitary function in CHARGE and VATER associations.

Authors:  V V Khadilkar; F J Cameron; R Stanhope
Journal:  Arch Dis Child       Date:  1999-02       Impact factor: 3.791

5.  Feeding difficulties in children with CHARGE syndrome: prevalence, risk factors, and prognosis.

Authors:  Cindy Dobbelsteyn; Sean D Peacocke; Kim Blake; William Crist; Mohsin Rashid
Journal:  Dysphagia       Date:  2007-11-20       Impact factor: 3.438

6.  Olfactory anomalies in CHARGE syndrome: imaging findings of a potential major diagnostic criterion.

Authors:  J Blustajn; C F E Kirsch; A Panigrahy; I Netchine
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-16       Impact factor: 3.825

Review 7.  Reproductive endocrine phenotypes relating to CHD7 mutations in humans.

Authors:  Ravikumar Balasubramanian; William F Crowley
Journal:  Am J Med Genet C Semin Med Genet       Date:  2017-11-20       Impact factor: 3.908

Review 8.  Phenotypic characteristics and variability in CHARGE syndrome: a PRISMA compliant systematic review and meta-analysis.

Authors:  Andrea T Thomas; Jane Waite; Caitlin A Williams; Jeremy Kirk; Chris Oliver; Caroline Richards
Journal:  J Neurodev Disord       Date:  2022-08-31       Impact factor: 4.074

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.